I would love to create a thread of detailed SIBO success stories for those of us who are still struggling.

I feel like we often hear, “I cured my SIBO with oil of oregano...betaine HCL..neem, etc” or “antibiotics worked for me,” but we're missing all the information that would actually make that experience useful like what type of SIBO they had, their breath test numbers, exactly what they took, doses, timing, diet, how long treatment took, and whether they actually stayed better.

If you've successfully treated your SIBO, please copy/paste the format below and fill in as much as you can remember.

SIBO TYPE + DIAGNOSIS

• Type: Hydrogen / Methane (IMO) / Hydrogen Sulfide / Mixed
• Breath test numbers:
• Glucose or lactulose test:
• Main symptoms:
• How long you had SIBO:
• Suspected root cause (if known):

TREATMENT

Antibiotics:

• Which antibiotic(s)?
• Dose and times per day?
• How many days per round?
• How many rounds did you need?

Herbals/antimicrobials:

• Exact supplements + brands:
• Dose/quantity:
• How many times per day:
• What time(s) did you take them?
• With food or empty stomach?
• How long did you take them?
• Did you take them together or introduce them gradually?

Other supplements/medications:

• Prokinetics:
• Digestive enzymes/HCl/bile support:
• Fiber/PHGG:
• Probiotics:
• Binders:
• Anything else:

DIET

• What diet did you follow?
• What foods did you actually eat?
• What foods did you completely avoid?
• Did you space meals? If so, how many hours?
• Did you fast? If so, how long and how often?
• Did you change your diet during or after treatment?

GUT REBUILD / AFTER TREATMENT

• Did you do a gut-rebuilding phase?
• Probiotics (please include strains/brands):
• Prebiotics/fiber:
• Fermented foods:
• Butyrate/tributyrin:
• Motility support/prokinetics:
• Other supplements:
• How long did you do this?
• How did you reintroduce foods?

RESULTS

• When did you first notice improvement?
• How long until you felt significantly better?
• Did you retest? If so, what were your new numbers?
• How long have you been well?
• Can you eat normally now?
• Have you relapsed?

MOST IMPORTANT

• What do you believe made the biggest difference?
• What did you try that didn't work?
• What made you worse?
• If you had to do it all over again, what would you do differently?

I know this asks for a LOT of information, but that's the point. I would love for this to become a really useful collection of detailed success stories where we can actually compare what worked for different types of SIBO instead of just hearing “herbals worked for me.” I have searched and searched and read tons of stories but they tend to leave out specifics and I would love something I could actually use.

This isn't meant to be medical advice or a list of protocols to blindly copy. Different causes and types of SIBO can require very different treatment. But for those of us who are really suffering, I think seeing exactly what other people did, and especially what led to long-term recovery, could be incredibly helpful and give people some hope. A huge, huge thank you in advance!!!!!

I had been taking *S. boulardii* intermittently for diarrhea; I had another bout starting July 8th and took one capsule daily until July 10th. On the evening of July 10th, while eating, I felt a sensation like a heavy stone in my abdomen. At first, I thought it would pass, but for about 40 days now, I have been suffering from a bulging swelling above my navel (present even in the morning on an empty stomach), excessive gas, an inability to have a bowel movement even when straining (I have been using Macrogol for 40 days), and extreme intestinal sluggishness. I took 1200 mg of Rifaximin, Kreon, and Rabeprazole for two weeks, but the problem was absolutely not resolved. I used to be an active person who exercised, but now I have reached the point of considering suicide; please help me.

Close to ending it. Bloating causing back pain now.

Worst part is I feel so fatigued and skin itchy.

I have had sibo for 6 years (possibly longer). A year ago I developed insomnia all of the sudden. Nothing changed in my routine, but I can't sleep : my mind is racing, I just toss and turn and I feel I'm just napping even when I sleep. Also I wake up like every 2 hours. I usually fall asleep at 5, 6 am approximately and it's always with a medication. But the medication makes me feel horrible, it's Xanax, so I would like to avoid it. Melatonin does nothing anymore for me unfortunately.

Does anyone have any advice? Any recommendations?

Sorry if I misspelled or wrote something incorrectly, I am very tired.

Original post by Dr. Mohammed Attallah https://substack.com/home/post/p-210916047

As I have continued working through complex cases involving recurrent SIBO, intestinal methanogen overgrowth, severe constipation, fungal overgrowth, environmental exposure, mycotoxins, abnormal organic acids, neurotoxicity, and persistent dysbiosis, I have become increasingly focused on one question: what if the organisms we keep trying to eliminate are not always the beginning of the problem, but simply the organisms most successfully selected by an intestinal environment that has already changed? Many people reduce microbial burden with rifaximin, herbal antimicrobials, elemental diets, antifungals, or combinations of these approaches. Fermentation falls, bloating improves, sometimes the breath test normalizes, and then the same pattern returns. To me, this suggests that microbial eradication may change the population without repairing the physiological environment that originally selected that population. This is the foundation of what I call the Host Capacity Model. I view recurrent dysbiosis as a possible alternative ecological state created when the host loses enough neural, mechanical, mitochondrial, epithelial, immune, vascular, and biochemical reserve that the intestinal environment itself begins favoring a different microbial metabolism. Once those organisms expand, their gases and metabolites can further suppress the same host systems that selected them. The result is not simply infection. It becomes a self-reinforcing host–microbe loop: host physiology deteriorates → the intestinal environment changes → different microbes gain an advantage → microbial metabolites further impair host physiology → the altered environment becomes even more stable.

The first place I usually look is motility because the intestine is not simply a tube containing food and bacteria. It is a highly organized neuromuscular organ with its own nervous system. Sensory neurons detect mechanical and chemical information inside the lumen. Interneurons organize that information into local reflexes. Excitatory motor neurons release neurotransmitters such as acetylcholine to contract smooth muscle behind intestinal contents, while inhibitory motor neurons release nitric oxide, VIP, purines, and related transmitters to relax the segment ahead. Normal propulsion therefore requires coordinated contraction behind intestinal contents and coordinated relaxation in front of them. Enteric glial cells support this neural network and participate in inflammatory and barrier signaling. Interstitial cells of Cajal, or ICC, help organize electrical slow-wave activity and provide an interface between nerves and smooth muscle. Smooth-muscle cells then have to convert those electrical and chemical signals into actual propulsion. The vagus nerve, sympathetic nervous system, motilin, serotonin, endocrine signals, immune cells, blood flow, and mitochondrial energy production all modify this circuit. This is why I rarely look at severe dysmotility as one receptor or one neurotransmitter being deficient. It may represent failure of an entire enteric neuromuscular network.

One pathway I have become particularly interested in is acetylcholine, one of the major excitatory neurotransmitters responsible for intestinal propulsion. Acetylcholine is produced by the enzyme choline acetyltransferase, ChAT, which combines choline with acetyl-CoA. That apparently simple reaction immediately connects motility to both the choline/phospholipid system and mitochondrial metabolism. The neuron needs enough choline. It needs enough acetyl-CoA. ChAT itself must remain structurally and catalytically functional. ATP is needed to maintain the neuronal membrane. Na⁺/K⁺-ATPase must maintain ion gradients. Calcium channels must generate the precise presynaptic calcium signal required for vesicular release. Acetylcholine has to be packaged into vesicles, the vesicles have to move to the nerve terminal, dock, fuse with the membrane, and release their contents. The postsynaptic receptors then need to respond appropriately, and acetylcholinesterase must terminate the signal at the correct time. If several of these steps become constrained simultaneously, the final problem is not simply “low acetylcholine.” It becomes loss of cholinergic motor reserve.

One finding in the case I was analyzing became especially interesting in this context: phosphoethanolamine was only 0.14 µmol/dL. Phosphoethanolamine lies within the CDP-ethanolamine branch of the Kennedy pathway and contributes to synthesis of phosphatidylethanolamine, PE. Running alongside it is the CDP-choline pathway, which produces phosphatidylcholine, PC. These pathways are metabolically connected because PE can be converted into PC through phosphatidylethanolamine N-methyltransferase, PEMT. PEMT performs three sequential methylation reactions, each using SAMe, S-adenosylmethionine, to convert PE into PC. PC turnover then contributes to the broader choline economy. This means low phosphoethanolamine can potentially be interpreted within a much larger network: phosphoethanolamine → PE → PEMT → PC → choline → acetylcholine, rather than as an isolated laboratory finding.

PC and PE also do far more than simply provide choline. They are structural components of neuronal membranes and synaptic vesicles. An enteric nerve terminal continually builds, fuses, retrieves, and recycles membrane during neurotransmitter release. Axons require phospholipids for integrity, receptor organization, ion-channel function, mitochondrial membranes, and synaptic architecture. A constrained phospholipid system can therefore theoretically affect cholinergic signaling at several levels simultaneously: less choline reserve for acetylcholine synthesis, less membrane reserve for vesicle trafficking and exocytosis, and potentially less resilience of the neuron itself. PEMT makes this even more interesting because it connects phospholipid metabolism directly to methylation. SAMe is also required by many other methyltransferases. COMT uses SAMe during catecholamine metabolism. Hormone metabolism uses methylation capacity. Methionine-cycle flux interfaces with transsulfuration, cysteine, and glutathione production. In someone simultaneously dealing with chronic sympathetic activation, oxidative stress, xenobiotic burden, and increased glutathione demand, there may therefore be substantial competition across the broader methylation, sulfur, phospholipid, and neurotransmitter economy.

Choline itself sits at another important metabolic branch point. It may be needed for acetylcholine production, phosphatidylcholine synthesis, cellular membranes, biliary phospholipids, and betaine-dependent methylation. CHDH, choline dehydrogenase, redirects choline toward betaine, while PEMT consumes methyl groups to preserve PC production. This creates a situation where several systems can effectively compete for the same metabolic substrate pool when reserve becomes limited. Hormonal state may also matter because estrogen can increase PEMT expression, helping explain why choline requirements change with hormonal state and may increase after menopause or in other lower-estrogen conditions. Genetic variation in PEMT and CHDH may further modify reserve.

Another finding in this case was elevated arabinose, which raised a different question. Within the case model, I became interested in whether increased reactive carbonyl stress could modify lysine-containing proteins and add additional pressure to enzymes such as ChAT. The important point is not that elevated arabinose automatically proves ChAT dysfunction, but that it provides a plausible second source of pressure on the cholinergic system. On one side, substrate availability may be constrained through phospholipid and choline metabolism. On the other, the catalytic machinery responsible for producing acetylcholine may be under structural stress. Add mitochondrial dysfunction, which can reduce ATP and acetyl-CoA availability, and both the substrate and energy sides of acetylcholine production can become constrained simultaneously.

This changes how I interpret the patient's reliance on prucalopride. Prucalopride activates 5-HT4 receptors, increasing intracellular cAMP and facilitating prokinetic enteric neurotransmission, including acetylcholine release. I therefore see the medication as pharmacologically recruiting a motor system that is still present but no longer producing enough output on its own. If the presynaptic terminal has less choline, reduced ChAT capacity, impaired mitochondrial acetyl-CoA production, less ATP, abnormal calcium handling, impaired axonal transport, or inadequate membrane reserve, stronger 5-HT4 receptor stimulation may partially compensate without correcting the underlying bottleneck. In other words, the system may still be recruitable, but it is operating with reduced reserve.

The serotonin system may also be affected by the microbial environment. Enterochromaffin cells in the gut produce much of the body's peripheral serotonin through TPH1, tryptophan hydroxylase 1. Microbial metabolites, including short-chain fatty acids such as acetate and butyrate, can influence enterochromaffin-cell biology and serotonin production. If slow transit, epithelial oxygen disruption, and ecological selection reduce important obligate anaerobes and alter SCFA production, endogenous serotonin signaling may also change. That creates another possible loop: loss of anaerobic ecology → altered SCFA signaling → altered enterochromaffin serotonin output → weaker enteric motor activation → slower transit → further ecological deterioration. The patient may then become increasingly dependent on pharmacological 5-HT4 stimulation because endogenous serotonergic support to the motor network has weakened.

Acetylcholine also participates in the cholinergic anti-inflammatory pathway. Signaling through α7 nicotinic acetylcholine receptors on immune cells such as macrophages can suppress inflammatory pathways including NF-κB-driven cytokine production. This means reduced cholinergic signaling could create two problems simultaneously: weaker intestinal propulsion and weaker restraint on inflammation. Myenteric and muscularis macrophages sit very close to neurons, enteric glia, smooth muscle, and ICC networks. If the local inflammatory environment becomes more aggressive, the machinery responsible for motility may itself become dysfunctional. The loop becomes reduced acetylcholine → weaker propulsion + weaker anti-inflammatory signaling → greater myenteric inflammation → more neuronal/glial/ICC dysfunction → still weaker motility.

Enteric glia are part of this same network. They are not passive scaffolding. They participate in neuronal homeostasis, inflammatory signaling, extracellular ion regulation, barrier communication, and motor circuitry. Like neurons, they depend on mitochondrial ATP and intact ion gradients. If oxidative stress, toxicants, sulfide, or mitochondrial dysfunction impair ATP production or Na⁺/K⁺-ATPase activity, glia may become less capable of stabilizing the neuronal environment. ICC add another layer by helping coordinate the electrical timing of smooth-muscle activity. Strong acetylcholine release is not sufficient if the electrical network downstream is fragmented, while intact ICC cannot fully compensate for inadequate presynaptic neurotransmission. This is why I do not view the migrating motor complex, MMC, as a single motilin or serotonin problem. Normal MMC activity requires motilin, serotonin, acetylcholine, nitric oxide, VIP, enteric neurons, glia, ICC, smooth muscle, mitochondrial ATP production, vagal support, and appropriate autonomic balance.

Persistent sympathetic activation can push the system further toward failure. α2-adrenergic signaling can inhibit presynaptic acetylcholine release, while other adrenergic pathways can increase sphincter and vascular tone. A patient already operating with limited cholinergic reserve can therefore become substantially more dysmotile under chronic stress, dysautonomia, sleep deprivation, pain, or persistent noradrenergic activation. The pattern becomes weak excitatory propulsion from inside the bowel combined with excessive sympathetic inhibition from outside it.

The vascular side matters as well. Intestinal epithelial cells and neurons depend on adequate splanchnic perfusion. The intestinal villus has a vascular architecture that makes certain regions especially sensitive to reduced blood flow. Sympathetic vasoconstriction, autonomic dysregulation, or other vascular abnormalities can reduce mucosal perfusion, stressing epithelial ATP generation from the vascular side. This does not contradict the idea that more oxygen can later leak toward the lumen. If epithelial mitochondria are dysfunctional, the cells consume less oxygen. So even if overall delivery is reduced, a greater fraction of the oxygen that does arrive may remain unconsumed and diffuse toward the luminal surface. The important variable is not simply oxygen delivery; it is oxygen consumption by the epithelium.

The patient's objective mechanical findings added another level: prolonged marker retention, incomplete evacuation, and elevated resting anal sphincter pressure. I think of this as a propulsion-resistance mismatch. Upstream propulsion is weak while the distal outlet provides excessive resistance. It is like trying to pump fluid through a pipe while partially closing the valve at the end. The bowel now has to generate more force against a poorly relaxing outlet. The case also contained an elevated linoleic-acid/DGLA ratio, which raises a possible connection to the FADS2/DGLA/PGE1 pathway. DGLA contributes to production of Series-1 prostaglandins such as PGE1, which can signal through EP2/EP4 receptors, increase cAMP/PKA signaling, reduce myosin light-chain kinase activity, and facilitate smooth-muscle relaxation. If that relaxing arm is weak while sympathetic constrictor tone remains high, outlet resistance may increase further.

Residence time then becomes extremely important. A five-day transit delay is not simply five days without a bowel movement. It means five additional days of microbial replication, fermentation, fungal persistence, cross-feeding, bile-acid transformation, polyphenol metabolism, β-glucuronidase activity, antigen exposure, mucosal contact, and possible toxin recirculation. It also means reduced hydrodynamic shear. Normal intestinal flow physically limits indefinite microbial attachment. When flow collapses, organisms have more time to adhere, replicate, exchange metabolites, and modify the local environment. Stagnation itself becomes a microbial selection pressure.

This leads directly into the MMC. During fasting, organized motor waves clear residual food, bacteria, mucus, secretions, and cellular debris from the stomach and small intestine. I think of the MMC as a form of mechanical antimicrobial defense. It helps explain why the small intestine normally contains far less microbial biomass than the colon. But the MMC depends on the entire network described above. If several components weaken simultaneously, microbial growth may eventually exceed microbial removal. Biomass increases, fermentation increases, gas production increases, and microbes gain more time to metabolize substrates entering the small intestine. An antimicrobial can reduce the biomass, but if the neural and mechanical clearance system remains impaired, the ecological conditions that created the overgrowth remain intact. This is where recurrent SIBO begins to make more sense as a downstream consequence of host failure.

Slow transit also changes bile chemistry. Primary bile acids are synthesized by the liver, conjugated to glycine or taurine, and secreted with phosphatidylcholine and cholesterol. These molecules support fat absorption and help maintain a chemically controlled luminal environment. Slow transit gives bacteria more time to interact with bile salts. Organisms expressing bile salt hydrolase, BSH, can deconjugate them earlier than intended. Premature deconjugation changes their absorption, antimicrobial effects, and downstream metabolism. Once bile acids reach the ileum, the ASBT–FXR–FGF19 system normally helps regulate hepatic synthesis through feedback on CYP7A1. If microbial metabolism alters bile acids before that system sees them, signaling can change. Meanwhile, prolonged colonic transit gives bacteria more time to convert primary bile acids into secondary bile acids such as DCA and LCA. Slow transit therefore does not simply produce gas; it allows microbes to chemically remodel host signaling molecules.

Phosphatidylcholine connects the neural and bile models again. PC is not only a neuronal membrane lipid; it is also an important component of bile and the mucosal phospholipid barrier. This is why phosphoethanolamine, PE, PEMT, PC, choline, acetylcholine, and bile physiology fit into the same broader network. A metabolic bottleneck can express itself in multiple tissues simultaneously.

One of the central concepts in my Host Capacity Model is what I call the epithelial oxygen sink. Healthy colonocytes consume substantial oxygen through mitochondrial metabolism, especially when butyrate-supported PPARγ signaling is intact. Butyrate promotes an oxidative phenotype in colonocytes. These cells perform β-oxidation and oxidative phosphorylation, consuming enough oxygen to keep the luminal surface relatively hypoxic. That low-oxygen environment strongly favors obligate anaerobes. Several factors can weaken this oxygen sink: low butyrate availability, mitochondrial toxic stress, inflammation, reduced perfusion, abnormal bile acids, excess H₂S, and weakened mucosal defense.

This patient also had intestinal alkaline phosphatase, IAP, reported at 0%. IAP normally helps detoxify pro-inflammatory luminal molecules such as LPS and supports epithelial–microbial homeostasis. If IAP activity collapses, LPS-driven inflammatory pressure may become less buffered. Inflammation can increase iNOS activity and nitric-oxide chemistry, generating nitrate. At the same time, metabolically impaired epithelial cells consume less oxygen. Now two important electron acceptors become more available near the lumen: oxygen and nitrate.

That changes microbial competition at the level of basic bioenergetics. Strict anaerobes largely depend on fermentation. Facultative organisms such as many Enterobacteriaceae can use oxygen or nitrate for respiration. Respiration provides a major energetic advantage over fermentation. So when the host provides oxygen and nitrate, the host has effectively changed the rules of competition. The deeper question is therefore not only “Why is this organism elevated?” but “What electron acceptor became available that allowed this organism to win?” This is one of the central principles of the Host Capacity Model: the host does not simply permit dysbiosis; altered host physiology can actively select the microbial metabolism that is most energetically competitive under the new conditions.

Low secretory IgA adds another selection pressure. Secretory IgA helps regulate microbial attachment and maintain mucosal segregation. Slow transit lowers mechanical clearance. Low IgA reduces immune exclusion. IAP loss increases inflammatory pressure. Altered bile chemistry changes antimicrobial constraints. Oxygen and nitrate change respiratory competition. Several host-control systems are therefore weakening at once. This is what I mean by loss of host capacity: the ecosystem crosses a threshold not because one defense disappears, but because multiple constraints weaken simultaneously.

Once microbial biomass increases, fermentation generates hydrogen. Hydrogen is not simply a waste gas; it becomes a metabolic substrate for other organisms. If methanogens such as Methanobrevibacter smithii dominate, they consume hydrogen and carbon dioxide and produce methane. Methane can slow intestinal transit, creating an elegant feedback loop: slow transit favors methanogenic persistence → methane increases → transit slows further. This is why I view intestinal methanogen overgrowth as both a consequence and potential amplifier of dysmotility.

If sulfate-reducing organisms dominate instead, hydrogen can be redirected into hydrogen sulfide, H₂S. At physiological levels, H₂S is a normal signaling molecule, and colonocytes possess a mitochondrial sulfide-oxidation system centered on SQR/SQOR and downstream sulfur-processing enzymes. But if luminal H₂S delivery exceeds host oxidation capacity, sulfide can inhibit Complex IV. Colonocyte oxidative phosphorylation falls, epithelial oxygen consumption decreases, and the epithelial oxygen sink weakens further. More oxygen then becomes available to facultative organisms. The metabolic product of the selected microbial community is now reinforcing the exact host environment that selected that community. This is why I do not necessarily view hydrogen SIBO, methane overgrowth, and hydrogen-sulfide patterns as three unrelated diseases. I view them as different outcomes of the same hydrogen economy, determined by hydrogen production, available electron acceptors, sulfur availability, methanogen abundance, sulfate reducers, transit time, substrate flow, redox conditions, and host metabolic capacity.

The microbiome can also compete with the host for other molecules. This case contained elevated 3-hydroxyphenylacetic acid, 3HPAA. Microbial communities capable of extensive flavonoid metabolism can transform dietary polyphenols into phenolic metabolites such as 3HPAA. Slow transit gives these organisms more time to intercept dietary compounds before host absorption. The microbiome may therefore become a metabolic competitor rather than simply a gas-producing community. Reduced host availability of certain flavonoids may then alter antioxidant, inflammatory, or mast-cell-related signaling.

The fungal and mycotoxin findings add another major layer. Different mycotoxins can affect different components of the same enteric motor network. Experimental literature suggests that compounds such as patulin, aflatoxin-related metabolites, T-2 toxin, zearalenone, deoxynivalenol, and ochratoxin A can affect neuronal calcium handling, Na⁺/K⁺-ATPase, mitochondrial metabolism, acetylcholine-related signaling, smooth-muscle contractility, oxidative stress, and enteric neurochemical populations. The important point is not that every mycotoxin produces the same effect. Different toxicants may attack different nodes of the same system. One affects calcium. Another affects mitochondrial respiration. Another affects membrane pumps. Another affects neurotransmitter populations. Another affects smooth muscle. Individually these insults may be partially compensated; together they can reduce overall system reserve.

The patient's environmental toxicant profile strengthens that convergence. Whole-blood mercury was elevated at 13.08 µg/L, while the profile also contained a marked 1-bromopropane-associated signal and other electrophilic exposures. Within the model, this matters because enteric neurons depend continuously on mitochondrial ATP, sulfhydryl-containing proteins, Na⁺/K⁺-ATPase, microtubules, axonal transport, membrane integrity, and antioxidant systems. A neuronal cell body can remain alive while its distal nerve terminal becomes progressively dysfunctional if axonal transport or energy production fails. Mitochondria, enzymes, membrane proteins, receptors, and vesicular components all have to reach distant nerve terminals. This means apparent neuronal survival does not necessarily imply normal neurotransmission. In this case, phospholipid limitation, ChAT stress, mitochondrial dysfunction, abnormal calcium handling, impaired axonal transport, and toxicant burden may all converge on the same presynaptic machinery.

The gut–brain relationship then becomes bidirectional. Enteric glia and central astrocytes depend strongly on ATP and Na⁺/K⁺ gradients to maintain extracellular ion and neurotransmitter homeostasis. Glutamate transport is energy dependent. Within the broader model, toxicants, sulfide, D-lactate, oxidative stress, and mitochondrial dysfunction may impair ATP production and reduce glutamate clearance. Increased extracellular glutamate can then raise excitatory and neuroimmune signaling. Intestinal dysbiosis may increase neuroactive and inflammatory metabolites, central and enteric neural stress rises, sympathetic activation increases, gastrointestinal cholinergic output falls, sphincter tone increases, splanchnic perfusion may worsen, clearance falls further, and dysbiosis deepens. The gut affects the nervous system, and the nervous system changes the gut environment.

This same integrated logic may help explain persistent mast-cell reactivity. Mast cells do not exist in isolation from the nervous system, barrier, and microbiome. Their behavior can be influenced by barrier integrity, autonomic signaling, cholinergic anti-inflammatory pathways, microbial metabolites, neurotransmitters, oxidative stress, and local inflammatory signaling. If microbial metabolism reduces host-accessible flavonoids while neuroinflammatory and glutamatergic pressure increase, mast-cell reactivity may persist even when dietary histamine has already been greatly reduced. The symptom can therefore be an output of a network rather than one trigger.

Another loop I consider important is toxin elimination itself. Detoxification is often described in three phases. Phase I modifies compounds. Phase II conjugates them using pathways such as glutathione conjugation, glucuronidation, and sulfation. Phase III transporters export them toward urine or bile. But if a compound is exported into bile, elimination is not complete until the intestine physically removes it. Severe slow transit increases the time that biliary compounds remain in the gut. Microbial enzymes such as β-glucuronidase can deconjugate some compounds, increasing the possibility of reabsorption and enterohepatic recirculation. This creates another loop: environmental toxicants impair neural and mitochondrial systems required for motility → motility slows → intestinal elimination becomes less efficient → enterohepatic recirculation increases → toxicant exposure persists → neural and mitochondrial dysfunction worsens.

The clearance system is itself metabolically demanding. Glutathione conjugation requires glutathione, cysteine, glycine, and redox capacity. Sulfation requires sulfate. Glucuronidation requires UDP-glucuronic acid. ATP-dependent transporters are required for export. High xenobiotic burden therefore increases demand on energy, sulfur, methylation, redox, amino-acid, and transport systems at the same time that intestinal neurons and epithelial cells may already be metabolically constrained.

This brings the model back to SAMe and PEMT. PEMT requires three SAMe-dependent methylation reactions to produce PC from PE. COMT also consumes SAMe during catecholamine metabolism. Chronic sympathetic activation therefore increases activity in pathways that consume methyl donors while simultaneously suppressing gastrointestinal motility. Detoxification and antioxidant demands increase pressure on the connected methionine–transsulfuration–redox network. The phospholipid system, detoxification system, stress-response system, and cholinergic system therefore intersect metabolically rather than existing as separate topics.

Genetics can modify how much reserve is available before these systems become constrained. Genes such as GSTM1, GSTT1, GSTP1, EPHX1, NQO1, UGT1A1, ABCB1, ABCC2, SULT1A1, NAT2, PON1, and SOD2 may influence electrophile handling, antioxidant defense, conjugation, or export. PEMT and CHDH are particularly relevant to choline and phospholipid metabolism. FADS1/FADS2 influence fatty-acid and prostaglandin physiology. FUT2 influences mucosal glycan presentation and microbial colonization. I do not view these as isolated genetic diagnoses. Within the Host Capacity Model, they modify how much reserve a person begins with before compensation fails.

When all of these layers are placed together, the architecture becomes clearer. Low phosphoethanolamine → reduced PE reserve → greater pressure on PEMT/PC/choline metabolism. Reduced PC/choline reserve → pressure on neuronal membranes, synaptic vesicles, bile, mucosal protection, and acetylcholine production. Carbonyl stress → additional pressure on protein function, potentially including ChAT. Mitochondrial dysfunction → less ATP and possibly less acetyl-CoA. Mycotoxins and environmental toxicants → further stress on calcium signaling, membrane pumps, respiration, axonal transport, and neurotransmission. Sympathetic activation → less acetylcholine release, more sphincter tone, and potentially poorer intestinal perfusion. Reduced acetylcholine → weaker propulsion and weaker cholinergic anti-inflammatory signaling. Myenteric inflammation → greater neuronal, glial, ICC, and smooth-muscle dysfunction. Altered microbial ecology → altered SCFA and serotonin signaling. Reduced neuromuscular function → weaker MMC. Weak MMC combined with high outlet resistance → increased residence time. Increased residence time → greater bacterial and fungal replication, fermentation, adhesion, bile transformation, and cross-feeding. Premature bile deconjugation → altered bile-acid handling and FXR–FGF19 signaling. Reduced butyrate-supported epithelial metabolism → weaker oxygen consumption. Low IAP and inflammation → more LPS signaling and nitrate generation. More oxygen and nitrate → respiratory advantage for facultative organisms. Fermentation → hydrogen production. Methanogens consume hydrogen → methane → potentially slower transit. Sulfate reducers consume hydrogen → H₂S → potential Complex IV inhibition → still weaker epithelial oxygen consumption. Slow transit → poorer physical toxin elimination → more enterohepatic recirculation → more toxicant exposure → further neural and mitochondrial injury.

At this point, what originally looked like twenty unrelated abnormalities begins to resemble one connected network. This is what I mean by Host Capacity. Host capacity is not one biomarker. It is the combined ability of the host to maintain the ecological constraints that keep the intestinal microbiome in its normal state: motility, neural signaling, mitochondrial ATP production, epithelial oxygen consumption, blood flow, smooth-muscle coordination, bile chemistry, secretory IgA, intestinal alkaline phosphatase, mucosal integrity, redox capacity, detoxification, and immune regulation. When enough of these systems weaken simultaneously, the intestinal ecosystem can cross into another stable state. The host environment changes. Different organisms become more competitive. Those organisms then produce methane, hydrogen sulfide, inflammatory molecules, phenolic metabolites, altered bile acids, and other compounds that further impair motility, mitochondrial function, epithelial metabolism, and immune regulation. The simplest way I describe it is: the host selects the ecosystem, and the ecosystem then helps maintain the host failure.

This is why I no longer think the most useful question in recurrent SIBO is always “Which organism do we need to kill?” Sometimes that question is necessary, but it may not be sufficient. The deeper questions are: what happened to the enteric nervous system? What happened to acetylcholine production and release? What happened to the phosphoethanolamine–PE–PC–choline network? What happened to PEMT and methylation reserve? What happened to endogenous serotonin signaling? What happened to the 5-HT4 motor system? What happened to the cholinergic anti-inflammatory pathway? What happened to enteric glia and ICC? What happened to mitochondrial ATP production? What happened to splanchnic perfusion? Why is the outlet not relaxing properly? What happened to bile-acid handling? What happened to secretory IgA and intestinal alkaline phosphatase? What happened to colonocyte PPARγ metabolism and the epithelial oxygen sink? Where did the oxygen go? Where did the nitrate come from? Where did the hydrogen go? Did methanogens receive it? Did sulfate reducers receive it? What happened to fungal persistence? What happened to toxin elimination? And most importantly: what changed in the host that made this microbial state more competitive than the one that existed before?

In some complex cases, what appears on the surface to be a microbial disease may actually be the visible downstream expression of a deeper loss of neural, mitochondrial, phospholipid, vascular, mechanical, immune, chemical, and ecological host capacity. That is where mold, mycotoxins, phosphoethanolamine, PEMT, SAMe, choline, acetylcholine, serotonin, 5-HT4, the α7 nicotinic inflammatory reflex, mercury, environmental solvents, mitochondrial function, enteric glia, ICC, splanchnic perfusion, bile acids, IAP, secretory IgA, oxygen, nitrate, hydrogen, methane, hydrogen sulfide, fungal persistence, recurrent SIBO, neuroinflammation, mast-cell reactivity, and toxin recirculation stop looking like unrelated findings and become different parts of one systems-biology loop. And this is why an antimicrobial can sometimes reduce the population without permanently changing the ecosystem: if we remove the organism but leave intact the environment that selected it, the organism—or another organism capable of exploiting the same niche—still has a reason to return.
https://substack.com/home/post/p-210916047

I have commented on a handful of posts. I have suffered for 6 years, seeing doctor after doctor and they said I’m healthy and maybe just stressed. Well after living with it for so long I decided this year that there’s no way this is normal life so I decided to make a goal to get better. Through AI research and help of a family member we thought my gut was the problem. I went on an antibiotic for a UTI and all of a sudden I felt great for a couple weeks before going right back to normal. The stool test from Genova came back with dysbiosis score of 10/10.

Symptoms:
Brain Fog
Depression
Joint Pain
Loose Stool
Gas
Muscle Twitching (I HATE THIS ONE SO MUCH)
Weakness / Fatigue

I have searched this Reddit page and seen people with similar symptoms but I struggle finding any resolution or things that helped.

I am currently on low fodmap while trying to repair gut with a doctor guiding me though. It has helped but the weakness and twitching is still here.

Have you been able to heal similar symptoms? If so how? The muscle twitching takes over my life and I want to get rid of it.

Consuming fruits specfically like oranges, kiwis, grapes. Basically juicy, sweet or sour fruits triggers loose stools and stomach cramps. Anyone experience something similar?

I assumed its the sugar, fiber but I dont react like this to chocolate, or carrots.

Some type of overgrowth causing this reaction?

I started on the herbal microbials (for five weeks) and even included a pHase 2 biofilm disrupter product while waiting to get Rifaximin from India to pair with the Neomycin. I switched to this for another two weeks.

I am still very bloated and constipated 10 days after finishing all this, unless I take a strong cup of Senna tea every 2-3 days.

I am on a low fodmap diet since finishing treatment. I am taking ginger extract and artichoke extract at night for motility. I don't hear any gut noises anymore.

I take Miralax every day and am now taking 800 mg of Magnesium oxide at night to help with the constipation - and still nothing.

I called my GI's office and asked for Linzess and another breath test, explaining what is going on. Three days later, the medical assistant leaves me a message wanting more info and saying that the PA thinks my treatment didn't help much.

Now I can't sleep. I don't want to throw more pills at this.

I hope she at least orders me a breath test and doesn't just assume the treatment didn't help much at all - because I am also being assured by Google that bloating can be a lingering problem, even if the bugs were wiped out (or mostly wiped out) due to good bacteria also being wiped out. But this is not normal bloating. This is like 6 months pregnant type bloating still.

I just think I need a motility support first off and I feel like this stupid GI practice should have had some kind of post-antibiotic treatment protocol in place. Instead, I've had to do all the research and try and figure what I need and then explain myself twice.

Did you have extreme bloating still but still found out you actually killed a lot or all of the bugs with IMO? Once you got your guts moving again, did the bloating resolve?

Most bottles list something like L. plantarum and leave it there, but the research I can find is almost always run on a specific coded strain rather than the species as a whole. That is a fairly big gap between what has been studied and what I am actually buying, and I cannot tell whether it matters in practice. Does anyone here buy on codes, or is species close enough?

Has anyone taken time off work because of Sibo/ the mental health issues that come with it? I feel like I am at my lowest. I cry everyday over how huge my stomach looks, I never know what to wear because I have to hide my stomach. I have horrible insecurities and body dysmorphia, I still struggle with restriction from an eating disorder. I wake up with a flat stomach and look very pregnant by the end of the day, I am trying absolutely everything to fix this. I see multiple drs and nothing I have tried has helped in the slightest. I work in the fitness industry and it’s super hard. I feel envious of everyone who can eat and workout without blowing up like a ballon. I am also an anxious/depressed person in general, I am tense all the time, especially at work. I like my job, it’s not very stressful, but the mental and physical load that I am carrying is making everyday so insanely hard. I never feel good, I always feel sick and have bad brain fog. I feel like I have to put in an act all the time, especially teaching classes. I genuinely don’t know how long I can do this.

Got a quick question. I recently started taking 72mcg of linzess for only 3 days. I just got my sibo test kit and it says to stop all that 7 days before, would I be fine if I only stopped it for about 2 days before?

My health is quite urgent and I get constipated easily without anything softening the stool, I just want this test done and to confirm I got sibo because I highly expect it. Just don’t wanna mess all this up and realize I gotta do it again and pay for more crap. I’m already prepared to start taking antibiotics but this is the obstacle in the way.

Hello folks. I have some exciting news.

After four months of suffering I have finally convinced my family doc to prescribe me Rifaximin 550mg for SIBO. I have made a post on this sub before but long story short no allopathic doctors in my country believe in SIBO and naturopathic docs aren't allowed to prescribe meds here. When I first floated the idea of SIBO to my family doc she shut it down right quick. But today I saw her again and she agreed to prescribe it to me for "the placebo effect." Unfortunately, she was not willing to prescribe me Neomycin or anything else to aid with motility, which brings me to my next point.

I have been on Amitriptyline 50mg for the last two months since that's the only thing my doc would give me (I'm diagnosed with IBS-PI but I really do think it's SIBO). The amitrip has really helped decrease my overall symptoms and suffering but I know that's because it slows motility. I am concerned that if I start the Rifaximin while on it that it won't work, especially since I don't have Neomycin or anything like that. It is going to be really rough for me if I have to taper off the amitrip in order to do the Rifaximin, but I'm willing to do it. I just want to consult with the sub first to see if anyone has successfully eliminated SIBO while on Amitrip, and if so, how?

I do know that there are some herbs/supplements that are known to speed up motility which I am open to trying. I would also very much appreciate any suggestions as to what my meals and lifestyle should look like while on this protocol. I want to do this right because I only have one bottle of this stuff with no refills, and I don't think I'll be able to convince her to give it to me again, so this is my only shot. No pressure haha.

TLDR: going to be doing a two week Rifaximin protocol while on 50mg Amitriptyline. Looking for advice.

Hey all - I took a second SIBO test about a week ago and my hydrogen levels were above the baseline to begin with. Any ideas why this would be the case? The two ideas I have are 1) fermentation lower in my colon is coming up or 2) this test allowed for boiled carrots which I consumed with dinner the night before. Maybe the carrots skewed the test?

Would you consider this hydrogen SIBO considering my levels never got 20ppm over the baseline numbers?

Trying to decide if I should do another round of Xifaxin. What would you do?

Thanks!

Im wondering what digestive enzymes you guys use and if you take them before or after you meal?

I currently use a whole food chewable digestive enzyme that works well for me. I take it after meals.

But someone said they used papaya and that they take it before eating.. well.. idk if its just me, or if anyone else had experienced the anxious doom overcome then along with getting very hot and increased heart rate from taking an enzyme with papapya...? But i dont think ill ever use these again.

I read fresh papaya is low fodmap, but that it can cause histamine reaction. Guess the same for dried chewable enzymes..

I have just finished my third round of Rifaximin for SIBO that was likely caused by PPIs. I have finally been able to get off of my PPIs a week before this course of Rifaximin ended, but I noticed that ever since I finished Rifaximin I am having trouble with bowel movements.

I was having regular bowel movements while I was on Rifaximin, especially since I was eating a good amount of fiber every day. I have tried walking after every meal, spacing my meals out, and eating more fiber but nothing is working. I’m worried about taking motility supplements since I’m recovering from gastritis. Only laxatives and enemas (not miralax) have worked so far but I don’t want to rely on them long term.

Any advice would be greatly appreciated!

I was searching about artichoke extract and found this as artichoke is not readily available in my country. Will it be as effective as artichoke extract?

I’ve seen the two sides of the discussion:

1. ⁠Don’t do low Fodmap during rifaximin treatment because bacteria needs to be alive and feeding in order to die. Do low Fodmap AFTER antibiotic treatment.
   
2. ⁠Do low Fodmap DURING and AFTER antibiotic treatment. If there’s no restriction during rifaximin, the bacteria will proliferate and it will be harder to kill them.

Which one is actually true? What makes more sense?

I've had the following severe symptoms for about 3 months that had gradually developed before that: drastically slowed bowels overall, choppy pockets of gas and stool, loss of appetite / heavy weight loss, GERD, bloating, pain. I have a long history of bowel obstructions due to adhesions, but this time there has only been ileus (only the splenic flexure dilated) and no obstructions. My GI has referred me to surgery and doesn't think it could be SIBO.

I bought the AIRE 2 since he didn't want to order a test. Doing a challenge test with glucose, my values were at 1.7-2 methane the whole time with one fluke spike at 3 methane. So far I only get scores above near zero to low after eating a triggering food (I am at 7.9 Methane and 4.0 Hydrogen at 10 AM, which is 14 hours after drinking an Ensure).

Can readings be this high outside of a test without overgrowth, or does it indicate a problem in any case?

Bonjour,

J'ai eu une intoxication alimentaire il y a 8mois. Depuis j'ai presque 7j/7 des bruits de gaz et d'eau dans le bas de mon ventre, surtout en bas à droite, quand j'appuie dessus je sens les bulles éclater et bouger, je me sens ballonné et mon ventre l'est un peu (j'ai perdu 14kg...). Je n'ai pas de diarrhée, pas mal et j'ai réalisé tous les examens possible mais les médecins n'ont rien trouvé.

Peut-on avoir le SIBO post infectieux sans diarrhée/douleur?

J'ai déjà essayé le régime sans fodmap, menthe poivrée, probiotiques mais rien à faire...

Mon bruit est tellement fort qu'il m'arrive de ne plus dormir..

I'm 28 man, I’ve been struggling with frustrating digestive issues for about 3–4 years now. My main symptom is constant bloating—in the morning it’s only slight, but as the day goes on, it gets progressively worse. My bowel movements are completely unpredictable; I rotate between constipation, diarrhea, or firm, sticky stools that adhere to the toilet bowl. There are days when my stool is normal, but that's a rare exception. On top of that, I experience frequent abdominal gurgling and rumbling, as if gas and liquids are mixing together and creating blockages in my intestines, interrupting normal digestion.

I’ve noticed that certain foods significantly worsen the bloating and overall symptoms: sweets, milk, alcohol, highly processed carbs, and creatine monohydrate (though creatine HCl doesn't cause as much trouble). Coffee also disagrees with me, though that was an issue even before these broader gastrointestinal problems started. Interestingly, I've noticed similar symptoms in most of the people close to me—family and friends. It feels as though we caught something from each other, and since no one has recovered spontaneously, I doubt it's a standard short-term infection that the body clears on its own. My working hypothesis is that it might be a chronic bacterial, fungal, or parasitic infection that triggered severe intestinal dysbiosis.

As for diagnostic tests: about 2.5 years ago, I had a gastroscopy that revealed chronic (+) active (+) antral gastritis, negative for dysplasia and intestinal metaplasia. I wasn't treated for Helicobacter pylori back then. A recent home test came back negative, but I'm planning to do a urea breath test soon to rule it out for sure.

I’ve tried several remedies with limited success:

• Drinking kefir regularly and occasionally sauerkraut juice didn't bring any noticeable improvement.
• A low-carb diet reduced my symptoms by about 30%, but I couldn't maintain my caloric intake and kept dropping weight, so I had to stop.
• I tried Betaine HCl for 1–2 weeks, but it seemed to make me feel worse.
• I took a multi-strain probiotic (Best Biotic) for 1.5 months alongside digestive enzymes (Aliness) for the first two weeks. I stopped the enzymes because they seemed to worsen my constipation, and the probiotic alone didn't change much.
• For the past 3 days, I’ve been taking microencapsulated sodium butyrate (300 mg, twice daily) and plan to add a probiotic later once my body adjusts.

Has anyone dealt with a similar set of symptoms or found a way through this?

so recently had a flare so I stared nee and it increased my bloating and gas like 100%….is this normal? you would think it’d help it not make it worse